![]() | Only 14 pages are availabe for public view |
Abstract The purpose of this study is to display the role of imaging by MRI in early detection and accurate diagnosis of chemotherapeutic neurotoxicity in neoplastic patients under chemotherapy. This study included 50 cases of different cancers with CNS radiological manifestations. The patients received chemotherapy according to their primary cancer protocol. Our result showed the role of MRI in detection of chemotherapeutic neurotoxicity occurs in cancer patients with different criteria of each The breadth of chemotherapeutic agents is vast, and adverse effects are, unfortunately, common. Distinguishing disease pathology from the adverse chemotherapeutic effects remains challenging (15). Chemotherapeutic agents cause both central and peripheral neurotoxicity. Central neurotoxic side effects of chemotherapy are the main reason to limit the dose of chemotherapy in many patients, despite the protective role of the blood–brain barrier (BBB) Cancer patients may experience a wide range of neurological symptoms due to chemotherapy. The development of these harmful effects may have an acute, subacute, or delayed course, and may be reversible or (partially) irreversible (14). Seizures, focal symptoms like aphasia or hemiparesis, and cortical blindness may occur as isolated symptoms (12). Magnetic resonance imaging (MRI) is a sensitive modality for evaluation of leukoencephalopathy (9). One of the most common MR finding features of neurotoxicity post chemotherapy is (PRES) which is a posterior reversible encephalopathy syndrome in which there is vasogenic edema within the occipital and parietal regions (~95% of cases), The edema is usually symmetrical (5). |